clinical trial · NCT06633328
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
Zhejiang University·early phase1·recruiting·n = 30
Aplastic AnemiaCD7 CAR-T cells injectionAllogeneic hematopoietic stem cell transplantation
brief summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia
started
Oct 20, 2024
primary completion
Oct 20, 2027
completion
Oct 20, 2027
last updated
Oct 9, 2024
detailed description
This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of CD7 CAR-T Bridging to allo-HSCT in the treatment of severe aplastic anemia.The primary endpoints are dose limiting toxicity (DLT) and the incidence of treatment emergent adverse event (TEAE).
official title
Clinical Study on the Safety and Efficacy of Donor Derived CD7 CAR-T Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the for Patients With Severe Aplastic Anemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol